Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Eye drops are widely accepted as formulations for targeting the anterior segment notwithstanding their limitations in terms of bioavailability. The unique structure of the eye requires specially-designed formulations able to favor the pharmacokinetic profile of administered drugs, mainly minimizing the influence of ocular barriers. Nanotechnology-based delivery systems lead to significant technological and therapeutical advantages in ophthalmic therapy. The aim of the present study was to determine whether tobramycin as ion-pair incorporated in mucoadhesive Solid Lipid Nanoparticles (SLN) reaches the inner parts of the eye favoring drug activity. After technological characterization of the tobramycin entrapped SLN formulation (Tobra-SLN), a pharmacokinetic study in rabbits after topical instillation and intravenous administration of the formulation has been carried out. In addition, the intracellular activity of Tobra-SLN formulation against phagocytosed Pseudomonas aeruginosa was investigated. The SLN were spherical in shape, and showed a hydrodynamic diameter of about 80nm, a negative zeta potential (-25.7mV) with a polydispersity index of 0.15, representative of a colloidal dispersion with high quality, characterized by an unimodal relatively narrow size distribution. As demonstrated by FTIR and DSC, tobramycin ion-pair could be concentrated into lipid inner core of SLN, without interaction with the stearic acid, thus promoting a slow and constant drug release profile in the dissolution medium. Surprisingly, the drug concentration was significantly higher in all ocular tissues after ocular and intravenous administration of Tobra-SLN formulation with respect to reference formulations and only Tobra-SLN allowed the penetration of drug into retina. Furthermore, the use of Tobra-SLN resulted in both higher intraphagocytic antibiotic concentrations in polymorphonuclear granulocytes and greater bactericidal activity against intracellular Pseudomonas aeruginosa, probably due to the ability of Tobra-SLN to penetrate either into phagocytic cells, or alternatively to cross bacterial barrier. The present study broadens the knowledge on the use of SLN as carriers for ocular drug delivery to the posterior chamber and might open new avenues for treatment of ocular infections, representing a strategy to overcome the microbial resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Challenges and obstacles of ocular pharmacokinetics and drug delivery
Urtti, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.027 · Cited by 1,003
Yu, D.-Y., & Cringle, S. J. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00027-6 · Cited by 653
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
The Blood-Retina Barrier: Tight Junctions and Barrier Modulation
Campbell, M., & Humphries, P. (2013) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-4711-5_3 · Cited by 270
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93 · cited 1×
“Even if in the last ten years SLN have been studied extensively and several manuscripts reported the advantage obtained by their use as delivery systems for many ophthalmic drugs (antiinflamatory, antiglaucoma, antiibacterial, antifungal), natural extracts, antioxidant molecules and gene therapy [9, 20, 21, 30-35], in…”
Background
Cited by
Mohammadi-Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 970
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Scioli Montoto, S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 652
Ocular Drug Delivery: a Comprehensive Review
Ahmed, S., Amin, M. M., & Sayed, S. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02516-9 · Cited by 352
Multidrug-Resistant Bacteria and Alternative Methods to Control Them: An Overview
Vivas, R., Barbosa, A. A. T., Dolabela, S. S., & Jain, S. (2019) · Microbial Drug Resistance · doi:10.1089/mdr.2018.0319 · Cited by 343
Qi, J., Hu, X., Dong, X., Lu, Y., Lu, H., Zhao, W., & Wu, W. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.05.009 · Cited by 292
Metadata
- Authors
- Chetoni, P., Burgalassi, S., Monti, D., Tampucci, S., Tullio, V., Cuffini, A. M., Muntoni, E., Spagnolo, R., Zara, G. P., & Cavalli, R.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 109
- Pages
- 214-223
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W2535405793
- Cited by
- 152
- References
- 6
- FWCI
- 7.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. https://app.cochat.ai/papers/10.1016/j.ejpb.2016.10.006
- The paper
- Chetoni, P., Burgalassi, S., Monti, D., Tampucci, S., Tullio, V., Cuffini, A. M., Muntoni, E., Spagnolo, R., Zara, G. P., & Cavalli, R. (2016). Solid lipid nanoparticles as promising tool for intraocular tobramycin delivery: Pharmacokinetic studies on rabbits. European Journal of Pharmaceutics and Biopharmaceutics. https://doi.org/10.1016/j.ejpb.2016.10.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.